NANOTHERAPY

A Novel Nano-container drug carrier for targeted treatment of prostate cancer

Coordinatore	"NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS"""    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Greece [EL]
Totale costo	2˙000˙000 €
EC contributo	2˙000˙000 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2008-AdG
Funding Scheme	ERC-AG
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-02-01   -   2014-01-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	"NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS"""  Organization address address: Patriarchou Gregoriou Str. city: AGHIA PARASKEVI postcode: 15310 contact info Titolo: Mr. Nome: Euripides Cognome: Papadopoulos Email: send email Telefono: +30 210 650 3037 Fax: +30 2106510594	EL (AGHIA PARASKEVI)	hostInstitution	2˙000˙000.00
2	"NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS"""  Organization address address: Patriarchou Gregoriou Str. city: AGHIA PARASKEVI postcode: 15310 contact info Titolo: Prof. Nome: George Cognome: Kordas Email: send email Telefono: 302107000000 Fax: 302107000000	EL (AGHIA PARASKEVI)	hostInstitution	2˙000˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The essence of the proposal is the fabrication of multiple nano containers which exhibit double and triple stimuli response and site recognition. Specifically, the containers will be grafted by Leuprolide (LP) for prostate cancer recognition. Multiple containers will be filled by two drugs (e.g. LP and DOX) in different compartments not interacting with each other chemically (cocktail of drugs, e.g. Container1 Leuprolide (LP) and Container2 Doxorubicin (DOX)). The release can be excited by internal or external stimuli response. The internal stimuli response of our nanocontainers will require simultaneous recognition of pH, redox and/or T of the tumour. The external induction will be caused by RF excitation (hyperthermia). The nanocontainers will identify the tumour first by the agonist (LP). After trapping the container at the tumour, they will be activated by the double and triple internal excitation. This way, we achieve extremely local chemotherapy of the diseased site and the healthy organs will be untouched. Our smart nanocontainers will be tuned for prostate cancer, but our system will be evaluated for other cases such as breast cancer and thrombosis. The containers will be modified (phase transition, volume change, degradation, etc.) and deliver the drug only and if only the two sensors give positive response. The containers can be excited by external induction (Radio Frequency (hyperthermia) RF or laser light). This revolutionary strategy is necessary because the externally induced delivery methods have the disadvantage that the radiofrequency fields, the magnetic fields and the laser lights are not local but they extend over large space, larger than the size of the tumour. One cannot focus from outside the laser beam directly to the tumour only may be due to lack of imaging facilities. Our technology will prevent the release of drugs in sites where the local values correspond to the healthy tissue.'